Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NMRD @Nasdaq $1.90 closing in on a $2 break! Nemaura Medical: Opportunity In The Consumer-Centered Continuous Glucose Monitoring Market
https://seekingalpha.com/article/4494374-nemaura-medical-opportunity-consumer-centered-continuous-glucose-monitoring-market #LongTerm #Gains
Sounds like a very interesting program. $NMRD
Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application.
$NMRD trading just under 2x its 10-day average volume as we start lunchtime... UP 1%.
$NMRD Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
Way undervalued at these levels!
$NMRD
Nemaura Medical to Present at the 24th Annual H.C. Wainwright Global Investment Conference https://conferencecalltranscripts.com/summary/?id=409475&pr=true
$NMRD
Nemaura Medical Inc is a medical device company revolutionizing non-intrusive glucose monitoring. $NMRD
Room to grow...great price to grab a starter. $NMRD
Thank you for sharing that link... $NMRD
Agreed...$NMRD has a great share structure.
Authorized Shares
42,000,000 09/01/2022
Outstanding Shares
24,102,866 09/01/2022
Restricted
17,920,204 09/01/2022
Unrestricted
6,182,662 09/01/2022
https://www.otcmarkets.com/stock/NMRD/security
$NMRD News August 15, 2022
Nemaura Medical, Inc. (NMRD) Reports Q1 Loss, Lags Revenue Estimates
https://finance.yahoo.com/news/nemaura-medical-inc-nmrd-reports-134501852.html
Nemaura Medical has a twelve month high of $17.40. $NMRD
$NMRD Top 10 Best Healthcare companies to Watch 2021 onwards! https://thesiliconreview.com/magazine/profile/10-best-healthcare-companies-to-watch-2021-listing/
Nemaura Medical Reports Fiscal First Quarter 2023 Results and Provides Business Update
August 15, 2022 (Globe Newswire)
Nemaura Medical, Inc. (Nasdaq: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today releases its financial results for the quarter ending June 30, 2022 and provides a business update.
Recent Corporate Highlights:
"We are very pleased with the progress we are steadily making with our manufacturing and commercialization support activities. Our daily wearable continuous glucose sensor is unique and innovative, offers lifestyle advantages over competing continuous glucose sensors, and has potential applications for people with diabetes and for the consumer wearable sensor market in general," commented Nemaura CEO Dr. Faz Chowdhury. "We continue to build an outstanding team of scientists, manufacturing personnel, engineers, and commercial managers to help advance the Company to the next phase of maturity and development. Importantly, given the current market climate, we are extremely pleased to have recently raised additional non-dilutive funding without any attached warrants or options, further strengthening our balance sheet as we anticipate growing our revenues in the coming quarters."
1Q23 Financial Summary:
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT and proBEAT. sugarBEAT, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEATdiabetes program that is currently undergoing pilot studies.
Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one's overall metabolic health and well-being. Nemaura believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.
For more information, please visit http://www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking Statements:
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura Medical's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners' ability to develop, market and sell proBEAT, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT digital health, and sugarBEAT. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The U.S. Food and Drug Administration (the "FDA") reserves the right to re-evaluate its decision that proBEAT qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical's filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.
Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD) Research Coverage Started at HC Wainwright
Posted by ABMN Staff on Mar 29th, 2022
Nemaura Medical logoEquities researchers at HC Wainwright began coverage on shares of Nemaura Medical (NASDAQ:NMRD – Get Rating) in a research report issued on Tuesday, The Fly reports. The firm set a “buy” rating and a $12.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 194.12% from the stock’s current price.
NMRD opened at $4.08 on Tuesday. Nemaura Medical has a twelve month low of $3.51 and a twelve month high of $17.40. The stock has a market capitalization of $98.33 million, a P/E ratio of -7.70 and a beta of -0.10. The company has a debt-to-equity ratio of 8.51, a current ratio of 1.55 and a quick ratio of 1.47. The stock has a 50-day simple moving average of $4.07.
Get Nemaura Medical alerts:
Nemaura Medical (NASDAQ:NMRD – Get Rating) last issued its quarterly earnings data on Friday, February 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).
A number of institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC grew its position in Nemaura Medical by 27.9% during the third quarter. Geode Capital Management LLC now owns 108,215 shares of the company’s stock valued at $650,000 after acquiring an additional 23,593 shares during the last quarter. Renaissance Technologies LLC raised its position in Nemaura Medical by 200.1% in the 3rd quarter. Renaissance Technologies LLC now owns 86,500 shares of the company’s stock worth $520,000 after purchasing an additional 57,674 shares during the period. Millennium Management LLC bought a new stake in Nemaura Medical in the second quarter worth $651,000. ARS Investment Partners LLC boosted its position in Nemaura Medical by 47.1% during the fourth quarter. ARS Investment Partners LLC now owns 61,863 shares of the company’s stock valued at $282,000 after buying an additional 19,799 shares during the period. Finally, Morgan Stanley grew its stake in shares of Nemaura Medical by 6,528.9% during the second quarter. Morgan Stanley now owns 50,313 shares of the company’s stock valued at $521,000 after buying an additional 49,554 shares during the last quarter. Institutional investors and hedge funds own 2.52% of the company’s stock.
Suspect this article https://www.techradar.com/news/could-the-apple-watch-7-really-measure-blood-glucose-and-why-is-it-important is reason for today surge
BOOM TOLD YA IMMINENT CATALYST Nemaura Medical to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021 https://www.globenewswire.com/news-release/2021/05/04/2222843/0/en/Nemaura-Medical-to-Participate-at-the-Benzinga-Global-Small-Cap-Conference-and-Present-to-Investors-on-May-14-2021.html
BACK TO 15 ON IMMINENT CATALYST
LOOKS LIKE THAT POWER HOUR/AFTERS TRAIN HAS BEEN BOARDING THE LAST HOUR LOL
U KNOW HOW SHE FLYS
I Like This Awesome Risk/Reward Level LOL But what do I know
BACK TO 15 ON IMMINENT CATALYST
BIG VOLUME NOW SHORTS READ THAT CHART TIME 2 JUMP TRACKS LOL
U KNOW HOW SHE FLYS
I Like This Awesome Risk/Reward Level LOL But what do I know
BOOM TRADELINE VWAP CROSSOVER NOW THEN ROCKET
BIG VOLUME COMING
SHORTS IMMINENT CATALYST COMING LOL
READ CHART U KNOW HOW SHE FLYS
I Like This Awesome Risk/Reward Level LOL But what do I know
$NMRD BOOM BIG VOLUME COMING
SHORTS IMMINENT CATALYST COMING LOL
READ CHART U KNOW HOW SHE FLYS
Shorts R Comfortable Now
Will Get Crushed
I Like This Awesome Risk/Reward Level LOL But what do I know
BOOM READ THE CHART UPCOMING CATALYST THE 14th
WATCHING FOR THAT TRAIN TODAY
Shorts R Comfortable Now
Will Get Crushed
I Like This Awesome Risk/Reward Level LOL But what do I know
* * $NMRD Video Chart 05-06-2021 * *
Link to Video - click here to watch the technical chart video
Out @ 15.44 > What a super low float running bull!
No I made a mistake, it was 15,000 shares.
8M trading float > you'll be a BILLIONAIRE!
I bought 400,000 more shares again today.
NMRD & GVSI > great combo >
Thanks buddy, keep an eye also AMS. Could make a run like RHE.
right on ... hope you make a killing :)
Why did I put 400,000 shares here, no, I meant to say 15,000 shares at 7.50. Either way it will continue to break the yearly high tomorrow.
* * $NMRD Video Chart 05-05-2021 * *
Link to Video - click here to watch the technical chart video
I made $500 on this scam today :)
I bought 400,000 more shares again today.
LOL SEE BOOM TOLD YA 2PM TRAIN RIGHT ON TIME BLOWIN SHORTS OFF TRACKS
READ CHART NOW SHORTS BIGGER/BIGGER VOLUME
THEY ARE TRAPPED
LOL BOOM TOLD YA READ CHART 2PM TRAIN COMIN DOWN THE TRACKS NOW SHORTS BIGGER/BIGGER VOLUME
CLOCK IS TICKIN
THEY WILL B TRAPPED
$NMRD $SSY $ISNS BOOM WATCH OUT FOR THAT 2PM TRAIN SHORTS CAUSE ITS COMING & NOT STOPPING TO PICK UP SHORT PASSENGERS LOL
NHOD LOL BOOM TOLD YA MAJOR BREAK OUT ON BIG NEWS NOW 8M LOW FLOAT
BIG RANGE LOOK LEFT ON THAT CHART ITS BEAUTIFUL
SHORTS ARE TOAST WATCH WHEN 2PM TRAIN ARRIVES
BOOM MAJOR BREAK OUT ON BIG NEWS NOW 8M LOW FLOAT
BIG RANGE LOOK LEFT ON THAT CHART ITS BEAUTIFUL
Going back to yearly highs tomorrow. Loaded 20,000 shares.
Going back to yearly highs tomorrow. Loaded 20,000 shares.
This presentation dated 7 Feb was followed by a spike on 8 Feb.
not a single post today, yet, up 25 to 40+ % all day.
Any news coming?
gp
Just In: $NMRD Nemaura Medical to Provide US proBEAT(TM) Launch Update at The LD 500 Virtual Conference
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose mon...
Got this from NMRD - Nemaura Medical to Provide US proBEAT(TM) Launch Update at The LD 500 Virtual Conference
News: $NMRD New Diagnostic Devices Help the Healthcare System Rally in Face of Severe Pressure
FinancialBuzz.com News Commentary New York, NY (7/23/2020) – The healthcare industry has made significant progress when it comes to efficiency and scope in the last several years, yet many complex issues remain unsolved. These issues are now particularly visible as the current pandemic ...
Find out more NMRD - New Diagnostic Devices Help the Healthcare System Rally in Face of Severe Pressure
News: $NMRD Nemaura Medical to Integrate Activity Data From Third Party Wearable Devices to Its proBEAT(TM) App
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose mon...
Read the whole news NMRD - Nemaura Medical to Integrate Activity Data From Third Party Wearable Devices to Its proBEAT(TM) App
News: $NMRD Distancing Measures Force Innovations in Patient Monitoring Procedures
FinancialBuzz.com News Commentary New York, NY (7/15/2020) – The current pandemic has created the need for new technologies in order to improve population-level screening and patient monitoring. One sector that has emerged in recent years and spiked in popularity this year is telemedici...
Find out more NMRD - Distancing Measures Force Innovations in Patient Monitoring Procedures
At least we got to see what’s inside the sharp looking box in last presentation
Followers
|
24
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1742
|
Created
|
04/28/17
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |